Trends in radiotherapy inpatient admissions in Germany: a population-based study over a 10-year period.

DRG data Germany Inpatient cases Non-radiotherapy departments Radiotherapy departments

Journal

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
ISSN: 1439-099X
Titre abrégé: Strahlenther Onkol
Pays: Germany
ID NLM: 8603469

Informations de publication

Date de publication:
Oct 2021
Historique:
received: 21 01 2021
accepted: 16 07 2021
pubmed: 4 9 2021
medline: 1 4 2022
entrez: 3 9 2021
Statut: ppublish

Résumé

With the increasing complexity of oncological therapy, the number of inpatient admissions to radiotherapy and non-radiotherapy departments might have changed. In this study, we aim to quantify the number of inpatient cases and the number of radiotherapy fractions delivered under inpatient conditions in radiotherapy and non-radiotherapy departments. The analysis is founded on data of all hospitalized cases in Germany based on Diagnosis-Related Group Statistics (G-DRG Statistics, delivered by the Research Data Centers of the Federal Statistical Office). The dataset includes information on the main diagnosis of cases (rather than patients) and the performed procedures during hospitalization based on claims of reimbursement. We used linear regression models to analyze temporal trends. The considered data encompass the period from 2008 to 2017. Overall, the number of patients treated with radiotherapy as inpatients remained constant between 2008 (N = 90,952) and 2017 (N = 88,998). Starting in January 2008, 48.9% of 4000 monthly cases received their treatment solely in a radiation oncology department. This figure decreased to 43.7% of 2971 monthly cases in October 2017. We found a stepwise decrease between December 2011 and January 2012 amounting to 4.3%. Fractions received in radiotherapy departments decreased slightly by 29.3 (95% CI: 14.0-44.5) fractions per month. The number of days hospitalized in radiotherapy departments decreased by 83.4 (95% CI: 59.7, 107.0) days per month, starting from a total of 64,842 days in January 2008 to 41,254 days in 2017. Days per case decreased from 16.2 in January 2008 to 13.9 days in October 2017. Our data give evidence to the notion that radiotherapy remains a discipline with an important inpatient component. Respecting reimbursement measures and despite older patients with more comorbidities, radiotherapy institutions could sustain a constant number of cases with limited temporal shifts.

Identifiants

pubmed: 34477888
doi: 10.1007/s00066-021-01829-7
pii: 10.1007/s00066-021-01829-7
pmc: PMC8458212
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

865-875

Informations de copyright

© 2021. The Author(s).

Références

Radiother Oncol. 2016 Apr;119(1):5-11
pubmed: 26922487
Strahlenther Onkol. 2011 Aug;187(8):449-60
pubmed: 21786109
Strahlenther Onkol. 2019 Jul;195(7):659-667
pubmed: 30498845
J Clin Oncol. 2018 Jun 7;:JCO2017762518
pubmed: 29878867
N Engl J Med. 2010 Aug 19;363(8):733-42
pubmed: 20818875
Radiother Oncol. 2014 Jul;112(1):140-4
pubmed: 24833561
J Community Support Oncol. 2015 Nov;13(11):399-404
pubmed: 26863020
Lancet. 2019 Jan 5;393(10166):51-60
pubmed: 30449623
Eur J Cancer. 2014 Oct;50(15):2735-43
pubmed: 25085229
Strahlenther Onkol. 2018 May;194(5):375-385
pubmed: 29302704
J Clin Oncol. 2012 Jun 1;30(16):1926-33
pubmed: 22529255
N Engl J Med. 2006 Feb 9;354(6):567-78
pubmed: 16467544
Lung Cancer. 2004 Jul;45(1):57-65
pubmed: 15196735
Lancet. 2019 Jan 5;393(10166):40-50
pubmed: 30449625
Radiother Oncol. 2016 Apr;119(1):145-9
pubmed: 26718152
Cancer Epidemiol. 2017 Oct;50(Pt B):257-259
pubmed: 29120833
Strahlenther Onkol. 2017 Jan;193(1):1-12
pubmed: 27628966
Laryngoscope. 2013 Dec;123(12):E97-103
pubmed: 23775348
Ann Oncol. 2007 Mar;18(3):581-92
pubmed: 17287242
Int J Radiat Oncol Biol Phys. 2014 Dec 1;90(5):1001-9
pubmed: 25539365
Radiother Oncol. 2005 Jun;75(3):355-65
pubmed: 16086915
Lancet Oncol. 2021 Jan;22(1):29-42
pubmed: 33301740
J Clin Oncol. 2010 May 1;28(13):2181-90
pubmed: 20351327
Lancet Oncol. 2013 Feb;14(2):e79-86
pubmed: 23352499
N Engl J Med. 2012 May 31;366(22):2074-84
pubmed: 22646630
Lancet Oncol. 2021 May;22(5):702-715
pubmed: 33862000

Auteurs

Daniel Medenwald (D)

Department of Radiation Oncology, University Hospital Halle (Saale), Ernst-Grube-Str. 40, 06120, Halle (Saale), Germany. daniel.medenwald@uk-halle.de.

Rainer Fietkau (R)

Department of Radiation Oncology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.

Gunther Klautke (G)

Department of Radiation Oncology, Chemnitz Hospital, Chemnitz, Germany.

Susan Langer (S)

Department of Radiation Oncology, University Hospital Halle (Saale), Ernst-Grube-Str. 40, 06120, Halle (Saale), Germany.

Florian Würschmidt (F)

Radiological Alliance, Hamburg, Germany.

Dirk Vordermark (D)

Department of Radiation Oncology, University Hospital Halle (Saale), Ernst-Grube-Str. 40, 06120, Halle (Saale), Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH